U.S. markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.64
    -0.81 (-3.44%)
     
  • EUR/USD

    1.1970
    +0.0057 (+0.48%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.32%)
     
  • USD/JPY

    104.0850
    -0.1650 (-0.16%)
     
  • BTC-USD

    18,112.69
    +344.63 (+1.94%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

U.S. FDA approves Roche, PTC Therapeutics' spinal muscular atrophy drug

Aug 7 (Reuters) - U.S. health regulators on Friday approved an oral treatment from Roche and PTC Therapeutics for spinal muscular atrophy, in adults and children two months of age and older.

The drug, risdiplam, will be sold under the brand name Evrysdi and compete with Biogen's Spinraza, the first medicine approved for the leading genetic cause of death in infants, and Novartis' gene therapy Zolgensma. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)